Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada

Deletion of the long arm of chromosome 13 (del(13q)) as the sole abnormality in chronic lymphocytic leukemia (CLL) portends a good prognosis; however, there is great outcome heterogeneity within this subgroup. The percentage of cells with a del(13q) (clone size) and the extent of the deletion are tw...

Full description

Saved in:
Bibliographic Details
Published inGenes chromosomes & cancer Vol. 55; no. 1; pp. 16 - 24
Main Authors Huang, Steven J. T., Gillan, Tanya L., Gerrie, Alina S., Hrynchak, Monica, Karsan, Aly, Ramadan, Khaled, Smith, Adam C., Toze, Cynthia L., Bruyere, Helene
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.01.2016
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Deletion of the long arm of chromosome 13 (del(13q)) as the sole abnormality in chronic lymphocytic leukemia (CLL) portends a good prognosis; however, there is great outcome heterogeneity within this subgroup. The percentage of cells with a del(13q) (clone size) and the extent of the deletion are two factors that may affect outcome in CLL patients with isolated del(13q). We analyzed 248 CLL patients from the BC Provincial CLL database identified as having isolated del(13q) detected pretreatment by interphase fluorescence in situ hybridization to determine what impact clone and deletion size had on overall survival (OS) and treatment free survival (TFS). Patients with 60% or more of nuclei with a del(13q) had shorter TFS and shorter OS. A large deletion, encompassing the RB1 gene locus, was detected in half of the 90 cases with available specimens for testing, and there was no significant difference in OS and TFS between RB1‐deleted and RB1‐not‐deleted cases. Further study in a larger sample size is required to determine the clinical interest of RB1 locus testing; however, clone size of del(13q) does predict TFS and OS and may better refine prognosis in this clinically heterogeneous population. © 2015 Wiley Periodicals, Inc.
Bibliography:ark:/67375/WNG-7RZL46SP-V
istex:321EF65355C90E484A71B3D0C6215DEC6637B093
ArticleID:GCC22294
Supported by: A Vancouver Coastal Health Research Institute grant; unrestricted grant‐in‐aid research funds from Roche Canada and Genzyme Canada were used to assist with database development; the VGH Hematology Research and Clinical Trials Unit (HRCTU).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1045-2257
1098-2264
DOI:10.1002/gcc.22294